Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.
about
In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory ApproachesThe role of disposable inhalers in pulmonary drug delivery.Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.Introduction: Aerosol delivery of orally inhaled agents.Pharmacokinetic studies for proving bioequivalence of orally inhaled drug products-critical issues and concepts.In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India.Methacholine challenge as a clinical bioassay of pulmonary delivery of a long-acting β₂-adrenergic agonist.Aerosol delivery to ventilated newborn infants: historical challenges and new directions.Establishing bioequivalence for inhaled drugs; weighing the evidence.Inhalation therapy in asthmatic and not asthmatic children.Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives.Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery.Orally inhaled fixed-dose combination products for the treatment of asthma and chronic obstructive pulmonary disease: not simple math.Opportunities in respiratory drug delivery.Nebulizers for drug delivery to the lungs.Factors to consider when selecting a nebulizer for a new inhaled drug product development program.Generation of tailored aerosols for inhalative drug delivery employing recent vibrating-mesh nebulizer systems.Industry guidance for the selection of a delivery system for the development of novel respiratory products.Nebulized drug delivery in respiratory medicine: what does the future hold?Long-term antibiotic treatment for non-cystic fibrosis bronchiectasis in adults: evidence, current practice and future use.Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers.A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.Inhalation devices and patient interface: human factorsPharmacokinetics of Orally Inhaled Drug Products.Regional particle size dependent deposition of inhaled aerosols in rats and mice.Switching from branded to generic inhaled medications: potential impact on asthma and COPD.Adherence monitoring in drug delivery.Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments.Considerations in establishing bioequivalence of inhaled compounds.Drug delivery to the lungs: challenges and opportunities.Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products
P2860
Q28080832-CAB342AF-D9F0-4D7D-954C-135D4FC5A809Q30368417-09A590B7-3B9B-4506-A405-51401B65A4AEQ33901651-5DECDD45-E3D1-45DE-B314-7E711BDDEC1FQ34487898-966E5A48-938F-4EEE-B29B-EEF98E0F7C1BQ35675762-E70FFF9A-9F58-4E1F-9686-260804B9370CQ35768368-14A01DA1-F26E-47F0-B5A9-05C764DD59C8Q35967928-C7A7D1BA-8CB1-4521-9EEE-036530855BBEQ37354536-061F4D14-7F04-4233-ADBF-F1CBCB89E968Q37794004-2DAF19D8-6E11-4D78-A8A5-D559CDCC87F3Q37893662-9D65CD78-8685-4936-9AD2-43475193917CQ37950135-30CAE373-7FF4-4821-9F1F-E0275A4F0107Q38084738-4B58B93E-C22C-4D24-B139-F96A791B3181Q38175421-E63384C1-95A7-41C6-A014-5CEA4BC0B4AAQ38193172-F8E11B3B-68AF-41F9-81AD-9B74C22DF179Q38297120-545FE6C6-3692-46D5-B73E-D3CC20DE65F9Q38298171-FBA1C48B-8FCB-486B-8888-71414F66A817Q38373085-A85B10EE-FE4F-4882-9892-DDEED1CE7D6AQ38498038-82509FCA-870A-4D8D-B10F-82CE003B479DQ38525610-69A1A2D0-F73A-4FE8-B9D4-517B0C2F7386Q38687910-CA6FE1E8-C5BB-4CFF-A9A3-C5FB5EBF62BDQ38797806-BA3DB951-4DB7-4C76-839F-EA73180D08DEQ39176996-6D34F892-7DA1-442A-B2F5-8B3D48D7F897Q42035782-464A26B9-C3C7-4083-90DD-4B15CC1233B4Q42118291-10FC089B-F2E9-4EA1-BE43-17C5D2A31D6CQ42593027-4005C984-A409-4685-AE5A-E8EF8991AB3AQ43468994-B83E6A27-4A10-499F-A4C8-07BD916B5800Q43538267-54F97B85-55A3-4CD7-826B-14225F96D3CDQ45882277-BC23662B-4EAB-48D7-B6D7-201090F8D624Q47659526-A4F1B36F-7994-4EA9-950E-D1FFFD79A74DQ47666210-60A0886D-1304-4A53-B9FD-F72560916CAFQ47825882-4F76CA79-2FA2-48A2-8102-386FDE0BA6DCQ58869538-5743D9D6-5F9F-46A5-AC37-C0F3A2259AA7
P2860
Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Demonstrating Bioequivalence o ...... IPs): Workshop Summary Report.
@en
Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products
@nl
type
label
Demonstrating Bioequivalence o ...... IPs): Workshop Summary Report.
@en
Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products
@nl
prefLabel
Demonstrating Bioequivalence o ...... IPs): Workshop Summary Report.
@en
Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products
@nl
P2093
P356
P1476
Demonstrating Bioequivalence o ...... IPs): Workshop Summary Report.
@en
P2093
Anthony J Hickey
Badrul A Chowdhury
Beth L Laube
Dale P Conner
David A Parkins
David Christopher
Dennis O'Connor
Gary R Pitcairn
Gur Jai Pal Singh
P356
10.1089/JAMP.2009.0803
P577
2010-02-01T00:00:00Z